Fantinato 2018.

Methods	Case‐control ‐ Brazil ‐ anaphylaxis related to MMR vaccine produced by manufacturer A and to assess associated risk factors
Participants	From 14 July 2014 to 12 January 2015, in children from 1 year to less than 5 years of age, vaccinated with MMR and reported with anaphylaxis; controls were without anaphylaxis. Cases n = 15, controls n = 60
Interventions	MMR vaccination manufacturer A
Outcomes	Anaphylaxis
Notes	The bivariate analysis of anaphylaxis and cow’s milk protein allergy showed OR 51.62, with P < 0.001 and 95% CI 5.59 to 476.11. The variables family food allergy, breastfeeding, previous postvaccine adverse event, and simultaneous vaccination were not statistically significant.